Bioavailability and bioequivalence: an FDA regulatory overview.
about
Anthocyanin Absorption and Metabolism by Human Intestinal Caco-2 Cells--A ReviewComparative testing and pharmacovigilance of biosimilars.Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.Bioactive equivalence of combinatorial components identified in screening of an herbal medicine.The use of isotopes in the determination of absolute bioavailability of drugs in humans.Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy.Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study.Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.A novel bioanalytical method based on UHPLC-HRMS/MS for the quantification of oleuropein in human serum. Application to a pharmacokinetic study.Biosimilars: how similar or dissimilar are they?Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteersFDA critical path initiatives: opportunities for generic drug development.International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences.Systems Pharmacology Dissection of the Integrated Treatment for Cardiovascular and Gastrointestinal Disorders by Traditional Chinese MedicineLack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.A systems-pharmacology analysis of herbal medicines used in health improvement treatment: predicting potential new drugs and targets.Requirements for generic antiepileptic medicines: a clinical perspective.Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes.Current regulatory approaches of bioequivalence testing.Phenolic compounds: their journey after intake.Bioequivalence of 2 azithromycin capsule formulations: a randomized, single-dose, open-label, 2-period crossover study in healthy male pakistani volunteers.A novel chemometric method for the prediction of human oral bioavailability.Bioequivalence assessment of two formulations of ibuprofen.Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.Evaluation of Bioequivalence of Two Long-Acting 20% Oxytetracycline Formulations in PigsA series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial.Bioavailability of phenolics from an oleuropein-rich olive (Olea europaea) leaf extract and its acute effect on plasma antioxidant status: comparison between pre- and postmenopausal women.Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules.Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an in vitro investigation.Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets.
P2860
Q26786966-AAF3D31D-C676-4B97-A82F-F8F7D56054DCQ30356696-7492A8FA-EBB6-4EA2-A26C-64DF8CE25B2FQ33506237-4589498D-046B-4C6B-AB15-F922B12E5627Q33775084-F5BE0A5A-7297-4F88-B3EB-CF0B520BB5EDQ34550493-8D128DF1-937B-428D-9E69-61E8BE711EFCQ35586444-7D0387C9-80C1-4B9E-A820-823FEADFD3AFQ35851994-4A1C9178-B7DF-415D-8F28-4156705558B9Q35967928-C327D55B-1E48-4BCF-B48F-937528952298Q36052246-D2A8646C-460B-4903-893B-D5BD678EBE96Q36556724-4299CAC8-A79D-4A11-BDFE-9C536F57E532Q37053912-52C2BA72-ACED-490B-BF2B-F9E5E26A4E03Q37150863-A7B87DEB-AB5E-40B4-934A-FF329F57AA9DQ37207811-8A3D3A7D-970F-4AD1-B21E-26A1B669A382Q37232687-371118A5-41C1-42D0-9C07-6C5EE583420BQ37321407-0A1D7530-AC47-47DA-840F-06CC6523CB76Q37393093-18BD6C3B-9BAF-48CB-A077-AF5C1B7E1545Q37888545-1BB94501-1412-4370-82C9-3D144A0951BCQ37964574-2451F321-F096-4E6E-B629-2E1CCB0EE48FQ38017304-804D1772-104B-4B55-B6B5-BCD8E7590DE3Q38171254-5F30967E-DF45-411B-9E3C-3AF0E7E2B4A2Q38310505-3C548626-3A0A-462E-A6A3-E261B145C914Q38323150-F1D0283B-160B-40DA-A0BB-BC38153B26B1Q38972382-E46D5CCD-8D93-496E-A51F-EC6A288EBDB2Q39401950-16EFAC7E-DF44-464F-A155-C68E195FC39CQ42290110-B2C9AE69-77C2-4599-8259-859ECE9EDE2CQ42374169-BE12FD84-C59B-4F50-91CB-B066F5267352Q45871028-95C891F3-78C4-48D2-9A31-3BD4B2AF9053Q47137075-0A7AFDFD-175C-45BB-8EEB-28A5B11768E9Q53554185-1D1EEDF0-1FB0-4DE0-98F4-A60454B63C3DQ54204498-694C0C27-2378-443B-B2C5-D1E3DBC58DDB
P2860
Bioavailability and bioequivalence: an FDA regulatory overview.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Bioavailability and bioequivalence: an FDA regulatory overview.
@ast
Bioavailability and bioequivalence: an FDA regulatory overview.
@en
Bioavailability and bioequivalence: an FDA regulatory overview.
@nl
type
label
Bioavailability and bioequivalence: an FDA regulatory overview.
@ast
Bioavailability and bioequivalence: an FDA regulatory overview.
@en
Bioavailability and bioequivalence: an FDA regulatory overview.
@nl
prefLabel
Bioavailability and bioequivalence: an FDA regulatory overview.
@ast
Bioavailability and bioequivalence: an FDA regulatory overview.
@en
Bioavailability and bioequivalence: an FDA regulatory overview.
@nl
P2093
P356
P1476
Bioavailability and bioequivalence: an FDA regulatory overview.
@en
P2093
Malinowski H
P304
P356
10.1023/A:1013319408893
P577
2001-12-01T00:00:00Z